论文部分内容阅读
目的观察地西他滨联合小剂量化疗治疗难治性白血病的临床疗效。方法将收治的难治性白血病患者68例,根据治疗方案的不同分为观察组和对照组各34例;对照组实施小剂量地西他滨化疗治疗,观察组实施地西他滨联合小剂量化疗治疗,对比2组患者临床疗效及不良反应发生情况。结果观察组总有效率为82.35%,高于对照组的70.59%(P<0.05)。观察组发生血液学毒性反应4例(11.76%),对照组发生血液学毒性反应5例(14.71%)(P>0.05)。结论对于难治性白血病患者,实施地西他滨联合小剂量化疗有较好的疗效,缓解率高,不良反应少,值得在临床中采纳及应用。
Objective To observe the clinical efficacy of decitabine combined with low-dose chemotherapy in the treatment of refractory leukemia. Methods Sixty-eight patients with refractory leukemia who were admitted to our hospital were divided into observation group and control group according to the different treatment regimen. 34 cases were treated with low-dose decitabine in the control group, Chemotherapy, compared two groups of patients with clinical efficacy and adverse reactions. Results The total effective rate in observation group was 82.35%, which was higher than that in control group (70.59%, P <0.05). In the observation group, hematologic toxicities occurred in 4 cases (11.76%) and in the control group in 5 cases (14.71%) (P> 0.05). Conclusion For patients with refractory leukemia, the implementation of decitabine combined with low-dose chemotherapy has better curative effect, high remission rate, fewer adverse reactions, it is worth in the clinical adoption and application.